Viral Vectors And Plasmid DNA Manufacturing Market Report 2026

Viral Vectors And Plasmid DNA Manufacturing Market Overview

• Viral Vectors And Plasmid DNA Manufacturing market size has reached to $7.11 billion in 2025 • Expected to grow to $20.36 billion in 2030 at a compound annual growth rate (CAGR) of 23.4% • Growth Driver: Increasing Gene Therapies Drive Growth In Viral Vectors And Plasmid DNA Manufacturing Market • Market Trend: Strategic Partnerships in Viral Vector and Plasmid DNA Manufacturing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Viral Vectors And Plasmid DNA Manufacturing Market?

Viral vectors and plasmid DNA manufacturing refers to the production processes involved in creating viral vectors and plasmid DNA, which are essential tools in gene therapy, vaccine development, and genetic research. The manufacturing of these components involves complex biotechnological processes to ensure the safety, efficacy, and consistency of the final products. The main types of products in the viral vectors and plasmid DNA manufacturing market are plasmid deoxyribonucleic acid (DNA), viral vector, and non-viral vector. Plasmid DNA refers to small, circular DNA molecules used in genetic research and biotechnology. These products are produced at different operational scales, including preclinical, clinical, and commercial levels. The market serves various therapeutic areas, including oncological disorders, rare diseases, neurological disorders, sensory disorders, metabolic disorders, musculoskeletal disorders, blood disorders, immunological disorders, and others, which are applied for gene therapies, cell therapies, and vaccines. Manufacturing in this market is carried out by both in-house manufacturers and contract manufacturing organizations (CMOs).

What Is The Viral Vectors And Plasmid DNA Manufacturing Market Growth Forecast?

The viral vectors and plasmid dna manufacturing market size is expected to see exponential growth in the next few years. It will grow to $20.36 billion in 2030 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to increasing approvals of gene and cell therapies, rising demand for commercial-scale manufacturing, expansion of CMO partnerships, growing focus on rare disease treatments, continued innovation in vector design and production efficiency. Major trends in the forecast period include increasing deployment of scalable viral vector manufacturing platforms, rising adoption of single-use bioprocessing systems, growing demand for high-purity plasmid dna, expansion of contract manufacturing capacity, enhanced focus on regulatory-compliant production.

Global Viral Vectors And Plasmid DNA Manufacturing Market Segmentation

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector 2) By Scale Of Operation: Preclinical, Clinical, Commercial 3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders 4) By Application Area: Gene Therapies, Cell Therapies, Vaccines 5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations Subsegments: 1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA 2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors 3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors

What Is The Driver Of The Viral Vectors And Plasmid DNA Manufacturing Market?

The increasing number of gene therapies is expected to propel the growth of the viral vectors and plasmid DNA manufacturing market going forward. Gene therapy involves introducing, removing, or altering genetic material within a person's cells to treat or prevent disease. Gene therapy advancement is essential due to growing investment in research and development of biotechnology, as well as a better understanding of genetic and cellular mechanisms underlying various diseases. Viral vectors and plasmid DNA manufacturing facilitate the delivery of therapeutic genes into patients' cells, enabling the treatment of genetic disorders at the molecular level. For instance, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials grew by 10% in Q3 2023, the first quarterly increase since Q3 2022. Therefore, the increasing number of gene therapies is driving the viral vectors and plasmid DNA manufacturing industry.

Key Players In The Global Viral Vectors And Plasmid DNA Manufacturing Market

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH

Global Viral Vectors And Plasmid DNA Manufacturing Market Trends and Insights

Major companies operating in the viral vectors and plasmid DNA manufacturing market are focusing on strategic partnerships to expand their production capacities, enhance technological capabilities, and accelerate the development and commercialization of gene therapies globally. Collaborations enable companies to share resources and infrastructure, increasing overall production capacity to meet the growing demand for gene therapies. For instance, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, and Captain T Cell, a spinoff from the renowned Max Delbrück Center in Berlin, Germany, launched a plasmid DNA and retrovirus vector production program agreement. The collaboration provides Captain T Cell with access to established contract development and manufacturing (CDMO) capabilities and advisory services. Additionally, it aims to accelerate the journey from preclinical research to clinical trials for a novel TCR-T cell therapy targeting solid tumors.

What Are Latest Mergers And Acquisitions In The Viral Vectors And Plasmid DNA Manufacturing Market?

In December 2023, Polyplus, a France-based biochemistry lab, acquired Xpress Biologics for an undisclosed amount. This acquisition will expand Polyplus' product portfolio and improve its capabilities in plasmid DNA production, which is crucial for gene and cell therapies. The move is expected to strengthen Polyplus' position in the rapidly growing field of gene therapy. Xpress Biologics is a Belgium-based contract development and manufacturing organization (CDMO) that specializes in producing plasmid DNA and proteins using microbial expression systems.

Regional Outlook

North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Viral Vectors And Plasmid DNA Manufacturing Market?

The viral vectors and plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as process development, cell line development, and analytical and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral vectors and plasmid DNA manufacturing market also includes sales of bioreactors, cell culture systems, reagents and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Vectors And Plasmid DNA Manufacturing Market Report 2026?

The viral vectors and plasmid dna manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors and plasmid dna manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.